Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
about
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinomaTreatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaUse of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus.Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Oncolytic viral therapies.Replication-competent herpes simplex vectors: design and applications.Herpes simplex virus 1 (HSV-1) for cancer treatment.Novel gene-directed enzyme prodrug therapies against prostate cancer.Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Oncolytic virus therapy for prostate cancer.HSV Recombinant Vectors for Gene Therapy.Clinical development directions in oncolytic viral therapy.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressMolecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy.Fibroblast growth factor and ornithine decarboxylase 5'UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN(-/-) transgenic mice.Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification.Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
P2860
Q33690926-D07389CF-5608-4435-B6CA-9D1C1D099D8FQ34313378-FC687315-186A-494A-8AF5-7421C3CF54DFQ34423157-B0404B3F-5643-4421-80E5-CEFCD7CE7A19Q34441869-54947581-C542-4F9C-A4E2-A0AB90EFCF95Q34557399-047B7F79-8D2F-43FD-8224-DA8838C1D1B6Q35649214-0403A102-7007-4AE3-8D38-A9CFE45359ACQ35699072-DC66BD1B-FA24-475E-B83A-3A82CF06F28DQ35852258-B1BC8301-9BF3-4206-843C-CEC927CBC370Q36288909-A732236B-1706-4D7B-9261-DC5356CE8DCAQ36444443-2E30495C-5AF2-4F9D-BF62-575D8B7DC66EQ36543076-98653516-F972-4B18-8361-BAE22212D874Q36755502-2CC55D8F-B4E3-4CA5-80D3-95B1521CFB51Q37615535-54D15189-1EE8-41A2-8C28-1BCADE741F54Q37787777-0844C26F-4E21-4D07-A69A-CA0C5E50A6AFQ37857659-6FB61210-E1D1-4853-9074-07E5DE22C97CQ37899230-A9EBF218-46EB-43DE-B46F-F3B80A80163DQ38500301-A9C026E5-2327-4191-880F-1DBCB0CEC108Q39473129-3EB11562-A5A8-4ABD-A109-2D21FF41CB7CQ39756417-E3E311D9-90C3-406B-A347-C390B5C632C0Q45423758-FAB8B027-D796-4CB0-B014-F0AC9BBBA373
P2860
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Oncolytic viral gene therapy f ...... neered herpes simplex viruses.
@en
type
label
Oncolytic viral gene therapy f ...... neered herpes simplex viruses.
@en
prefLabel
Oncolytic viral gene therapy f ...... neered herpes simplex viruses.
@en
P2093
P2860
P356
P1433
P1476
Oncolytic viral gene therapy f ...... neered herpes simplex viruses.
@en
P2093
Amit Bhargav
Paul J Cozzi
Peter B Burke
Peter T Scardino
Warren D W Heston
P2860
P304
P356
10.1002/PROS.10138
P50
P577
2002-10-01T00:00:00Z